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was discontinued early; only safety results from this group are presented. For the 
armodafinil 150 mg group compared with placebo, there was a significantly 
greater decrease in LS mean (SEM) IDS-C30 total score (−21.7 [1.11] vs −17.9 [1.10]; 
P=0.0097) at week 8 and the percentage of IDS-C30 responders (≥50% decrease 
from baseline) was significantly greater at week 8 (55% vs 39%; P=0.0084) and 
final visit (46% vs 34%; P=0.0147). The most common AEs were headache (9.6% vs 
10.1%), diarrhea (8.6% vs 6.5%), and nausea (5.6% vs 4.5%) for the armodafinil 150 
mg and placebo groups, respectively, and headache (21.9%), insomnia (12.5%), 
and nausea (9.4%) for the armodafinil 200 mg group. At final visit, 5% (9/183) of 
patients in the placebo group, 2% (3/186) of the 150 mg group, and 4% (1/28) of 
the 200 mg group had potentially clinically significant (≥7%) weight gain from 
baseline. CONCLUSIONS: Armodafinil 150 mg significantly improved depressive 
symptoms compared with placebo in patients with a major depressive episode 
associated with bipolar I disorder when given as adjunctive treatment to mood 
stabilizers. Safety data indicate that adjunctive armodafinil 150 mg was generally 
well tolerated.  
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OBJECTIVES: Levomilnacipran (1S, 2R-milnacipran) is a potent and selective 
serotonin and norepinephrine reuptake inhibitor (SNRI) with approximately 2-
fold greater potency for reuptake inhibition of norepinephrine than serotonin. A 
sustained release (SR) formulation was developed for once-daily dosing. 
Levomilnacipran SR is in late-stage clinical development for major depressive 
disorder (MDD). Analyses were conducted to evaluate the long-term benefits of 
levomilnacipran SR treatment on the functional health and well-being of adult 
MDD patients as measured by the SF-36v2 Health Survey. METHODS: Patients 
with MDD who completed 1 of 3 placebo-controlled studies (lead-in studies) were 
eligible to participate in this open-label extension study (NCT01034267), 
consisting of a 48-week open-label treatment period with levomilnacipran SR 40-
120 mg/d. The mean change from baseline (start of lead-in study) to end of study 
for each individual health domain [Physical Functioning (PF), Role Physical (RP), 
Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role 
Emotional (RE), Mental Health (MH)], and the Physical (PCS) and Mental (MCS) 
Component Summary scores were analyzed using Last-Observation-Carry-
Forward (LOCF) and Observed Cases (OC). RESULTS: A total of 811 patients in the 
intent-to-treat population had a baseline SF-36 evaluation; 758 (LOCF) and 378 
(OC) patients completed 48-weeks of treatment in the extension study. With the 
exception of PCS, which had baseline scores (mean±SD: 50.60±10.91) within the 
normal range, improvement from baseline was seen for the MCS (baseline: 
18.97±9.22) and all individual health domains, which was maintained over the 
course of the study period. Changes from baseline at week-48 were: MCS (LOCF: 
22.04±16.95, OC: 26.53±15.42); PF (3.96±10.26, 5.48±10.53); RP (6.29±13.21, 
8.45±13.01); BP (5.17±11.82, 7.01±11.57); GH (6.16±9.39, 8.01±9.49); VT (14.84±13.28, 
18.51±12.76); SF (16.55±14.70, 20.24±13.52); RE (17.47±15.39, 20.87±14.32); MH 
(18.10±14.76, 22.19±13.62). CONCLUSIONS: Long-term treatment with 
levomilnacipran SR in patients with MDD resulted in sustained improvement in 
functional health and well-being as measured by the SF-36.  
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OBJECTIVES: Describe changes in Clinical Global Impressions Severity (CGI-S) 
scores for adults with schizophrenia and/or schizoaffective disorder recently 
initiated on a new oral atypical antipsychotic (OA) or paliperidone palmitate (PP). 
METHODS: Adults with schizophrenia and/or schizoaffective disorder captured 
in the Duke Mindlinc EMR system (1/1/2010- 12/31/2011), with >90 days of 
treatment with the index therapy (first PP or OA prescription following a switch), 
CGI-S score at baseline, 1 or more CGI-S scores over 90 days post-index, and data 
activity 180 days prior to and 270 days post-index (proxy for eligibility). CGI-S 
scores were evaluated in two 90-day windows prior to and three 90-day windows 
post-index date. Changes in CGI-S over time were assessed using Cochran-
Mantel-Haenszel tests and generalized estimating equation models. RESULTS: A 
total of 980 patients (63 PP/917 OA) met all criteria. Patients were of similar mean 
age (PP 41+SD 11.5; OA 39+11.6; p=0.2011) and gender (female: PP 48%; OA 49%; 
p=0.8626). PP patients showed significantly greater CGI-S at baseline (PP 4.8+1.0); 
OA 4.3+1.1; p=0.0011), more comorbidities, and a higher percentage hospitalized 
180 days prior to index (PP 22%; OA 11%; p=0.0075). While changes in CGI-S over 
time (Time -2, Time -1, Baseline, Time 1, Time 2, and Time 3) were modest, CGI-S 
Scores for PP patients (PP- 4.5+1.4, 4.6+1.5, 4.8+1.0, 4.6+1.0, 4.4+1.1, 4.2+1.3) 
showed greater improvement over time versus OA patients (OA- 4.1+1.2, 4.2+1.2, 
4.3+1.1, 4.1+1.1, 4.2+1.1, 4.1+1.2). CONCLUSIONS: In this ‘real-world’ evaluation of 
CGI-S scores using EMR data, PP patients showed an improvement over time 
while OA patients remained relatively flat.  
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OBJECTIVES: Identify clinical features, findings on CT and MRI of the brain and 
the determination of herpes virus 1, 2 and 6 in cerebrospinal fluid (CSF) by 
Western Blot test and PCR. METHODS: Was performed on all patients admitted 
to the Department of Neurology Specialty Hospital National Medical Center 
Century XXI, IMSS, in the period of March 2009 on the date 2011 that date who 
had symptoms and signs related acute herpes encephalitis. A clinical history and 
complete neurological examination were realized. Was obtained by lumbar 
puncture for cytochemical cerebrospinal fluid, cytological, culture, Herpes 
antigens 1, 2, 6 and precipitated DNA was obtained by PCR for the determination. 
RESULTS: Twelve patients positive for herpes virus 1, 2 and 6. The most 
outstanding neurological characteristics of these patients were: headache in 10 
of the 12 patients, (83%) and confuse state in 10 of the 12 patients, (83%), in the 
CSF, was identified lymphocytic pleocytosis in all the patients in a range of 7 a 
500 cells an average value of 110, high protein in all patients from 38 to 322 mg/dl 
range an average 124.4. The main findings in CT and RM were bilateral 
hypodensity, multifocal extratemporal injury and ventricular dilatation and 
magnetic resonance signal change in temporal or extratemporal regions with 
enhancement in lesions, all patients were treated with acliclovir. At follow-up at 
6 months: No reported deaths and major sequelae secondary symptomatic 
epilepsy and mild cognitive impaire CONCLUSIONS: The herpes virus positive 
patients 1,2 and 6 show an early diagnosis of encephalitis and remains an urgent 
neurological identify characteristics and initiate early comprehensive 
management including acyclovir to reduce morbidity and mortality in this 
patient group.  
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OBJECTIVES: Despite buprenorphine’s promise as a novel therapy for opioid 
dependence, little is known about its clinical adoption. We characterized trends 
in ambulatory use and sales of buprenorphine and methadone in the United 
States. METHODS: Cross-sectional analyses of buprenorphine and methadone 
utilization and sales using data from the IMS Health National Disease and 
Therapeutic Index, a nationally representative survey of ambulatory care (1997-
2012), the IMS Health National Prescription Audit, reflecting retail, long-term 
care and mail-order pharmacy sales (2007-2011), and the IMS Health National 
Sales Perspective, capturing distribution of products from manufacturers to 
suppliers (2007-2011). RESULTS: Between 2003 and 2011, there was a sharp 
increase in buprenorphine ambulatory treatment visits, with an annual rate of 
increase of approximately 37%, reaching nearly 2 million treatment visits during 
2011. During this period, the proportion of buprenorphine treatment visits 
accounted for by psychiatrists decreased from 92% to 37%. Two-thirds of 2011 
treatment visits were for individuals 20-39 years of age, while 91% of these visits 
were for drug abuse or dependence and 90% involved the use of combination 
buprenorphine/naloxone (Suboxone) rather than other buprenorphine products. 
Between January 2007 and December 2011, there were modest increases in retail 
pharmacy prescriptions for methadone, from approximately 325 to 375 thousand 
monthly prescriptions. By contrast, buprenorphine sales increased by an average 
of 40% annually during this period, from approximately 0.5 million during the 
first quarter of 2007 to 2.7 million during the last quarter of 2011. Despite these 
increases, methadone sales from manufacturers to distributors remained 
generally steady and four-fold greater than buprenorphine sales. CONCLUSIONS: 
Since 2003, there has been a large increase in buprenorphine utilization. While 
the impact of increases in buprenorphine use on the epidemic of prescription 
opioid abuse remains to be examined, the increases reflect a substantial shift in 
the landscape of opioid dependence treatment.  
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OBJECTIVES: Stimulants are recommended first-line treatments for attention 
deficit hyperactivity disorder (ADHD), but increased use of other psychotropic 
medications such as antipsychotics and antidepressants has been reported. 
However, recent nationally representative estimates are lacking. This study 
examined the recent trends in use of psychotropic medications among children 
with ADHD in the US. METHODS: This retrospective study utilized the data from 
Medical Expenditure Panel Survey for the years 2002-2010. Trends in use of 
psychotropic medications (stimulants, antipsychotics, antidepressants, 
anxiolytics/sedatives/hypnotics, mood stabilizers and clonidine) were examined. 
Unadjusted logistic regressions were conducted to assess the significance of 
trends in medication use over time. Logistic regressions were conducted to 
identify the socio demographic characteristics and comorbid psychotic disorders 
(schizophrenia, bipolar disorder, depression/anxiety, autistic disorders) 
associated with the use of each psychotropic medication class. RESULTS: Use of 
stimulants was most common during the study period, which increased sharply 
from 43.0% in 2002 to 80.8% in 2006 but decrease afterwards to 62.2% in 2010. Use 
of antidepressants accounted for 10.4% and with no statistical significant trend 
over time annually. Antipsychotics was used for 9.3% of ADHD children annually 
but increased in recent years from 7.2% in 2002-2004 to 11.3% in 2008-2010 (OR: 
1.6, 95% CI: 1.1-2.6). Having schizophrenia (OR 26.6: CI 2.95-239.6) or bipolar 
